ID: ALA5266265

Max Phase: Preclinical

Molecular Formula: C12H9N3O3

Molecular Weight: 243.22

Associated Items:

Representations

Canonical SMILES:  COc1ccc2oc(-n3cncn3)cc(=O)c2c1

Standard InChI:  InChI=1S/C12H9N3O3/c1-17-8-2-3-11-9(4-8)10(16)5-12(18-11)15-7-13-6-14-15/h2-7H,1H3

Standard InChI Key:  ZZFNVUDOVPFZFA-UHFFFAOYSA-N

Associated Targets(Human)

Monoamine oxidase A 11911 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 243.22Molecular Weight (Monoisotopic): 243.0644AlogP: 1.38#Rotatable Bonds: 2
Polar Surface Area: 70.15Molecular Species: NEUTRALHBA: 6HBD: 0
#RO5 Violations: 0HBA (Lipinski): 6HBD (Lipinski): 0#RO5 Violations (Lipinski): 0
CX Acidic pKa: CX Basic pKa: CX LogP: 1.35CX LogD: 1.35
Aromatic Rings: 3Heavy Atoms: 18QED Weighted: 0.68Np Likeness Score: -0.91

References

1. Madhav H, Jameel E, Rehan M, Hoda N..  (2022)  Recent advancements in chromone as a privileged scaffold towards the development of small molecules for neurodegenerative therapeutics.,  13  (3.0): [PMID:35434628] [10.1039/d1md00394a]

Source